Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.

Also called NCT01756430

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 238 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01756430
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01756430. Randomized; triple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
Condition
Hypertension
Intervention (Drug)
Carvedilol SR 32mg, QD
Intervention (Drug)
Carvedilol SR 64mg, QD
Intervention (Drug)
Carvedilol IR 25mg, QD
Intervention (Drug)
Carvedilol IR 25mg, BID
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01756430
Content hash
f9fd7ce1ca57f7419fb965434896d94c7261a92f863d9f4fb5697bb148808956